This company listing is no longer active
Zymergen Management
Management criteria checks 0/4
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 1.2yrs |
| Board average tenure | no data |
Recent management updates
Recent updates
Zymergen chief scientific officer to depart as company lays off more employees
Aug 25Zymergen: Ginkgo Bioworks Acquisition
Jul 26Zymergen expands agreement with Octant on developing breakthrough medicines
Jul 14Zymergen Seeks Turnaround But Runway Is Running Low
Jun 03Zymergen: A Humbled Company With A Business On The Ropes
May 23Some Zymergen Inc. (NASDAQ:ZY) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 27
Zymergen Inc. (NASDAQ:ZY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Zymergen: Total Chaos
Dec 09Zymergen: How To Buy A Disaster
Aug 05Analysts Just Made A Major Revision To Their Zymergen Inc. (NASDAQ:ZY) Revenue Forecasts
Aug 05CEO
Zymergen has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Financial Officer | 8.2yrs | US$5.13m | 0% $ 0 | |
| Chief Technology Officer | less than a year | no data | no data | |
| Director of Communications | no data | no data | no data | |
| Chief Commercial Officer | 1.2yrs | no data | no data | |
| Chief Development Officer | 1.2yrs | no data | no data | |
| Senior Vice President of Drug Discovery | less than a year | no data | no data | |
| Secretary | no data | no data | no data | |
| Corporate Secretary | no data | US$1.81m | 0.037% $ 94.2k |
Experienced Management: ZY's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/23 13:29 |
| End of Day Share Price | 2022/10/18 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zymergen Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Matthew Sykes | Goldman Sachs |
| Sriharsha Pappu | HSBC |